Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Review which Dividend Aristocrats ETF has the highest management fee and how it affects net performance.
28,021 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A Qatar-linked LNG carrier crossed Hormuz, the first export through the strait since the war intensified. The move co...
A former battery designer explains how America can reclaim global leadership by building next-gen materials on domest...
Panorama Mortgage Group is folding its various brands into a single banner, SimplyPMG, and naming Fernando Ospina as ...
A November-like standoff erupts as MRED suspends Zillow’s access to Chicagoland listing data, potentially reshaping h...
As AI-focused crypto assets roar, Pi Network faces a defining year. This report weighs whether will network (pi) outp...
SpaceX going public could redefine the balance of big-name holdings in passive portfolios. This guide explains what b...
Meta Platforms trades near the $630s as investors weigh AI-driven capex against margin gains. A growing capital bill ...
A hotter-than-expected inflation reading paired with robust payroll gains left the newly named Fed chair navigating a...
New York is weighing a first-of-its-kind rule to block gun prints at the printer. The plan, while aiming to curb ghos...
Retirees eyeing Mexico’s Pacific coast weigh a $2,500-a-month budget. This report breaks down costs, healthcare optio...
A former Google engineer who left India builds Nebula AI into a $7.2 billion AI powerhouse in the U.S., highlighting ...